Jan 8 (Reuters) – Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
Aktis is targeting a valuation of up to $945.4 million in the IPO.
(Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich)
Brought to you by www.srnnews.com